Clinical trial
Micafungin Salvage Mono-therapy in Invasive Aspergillosis
NCT00376337 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00376337 |
|---|---|
| Title | Micafungin Salvage Mono-therapy in Invasive Aspergillosis |
| Official title | A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Invasive Aspergillosis |
| Intervention type | Drug |
| Interventions | Micafungin, Systemic antifungal therapy |
| Enrollment | 17 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 14, 2006 |
| Last update posted | Sep 5, 2013 |
| Countries | Argentina, Belgium, Brazil, Colombia, Croatia, Czechia, France, Germany, Hungary, Italy, Poland, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: